title: Schizophrenics with small P300: a subgroup with a neurodevelopmental disturbance and a high risk for tardive dyskinesia?
abstract: Schizophrenics with a neurodevelopmental disturbance resulting in micro- and macroanatomical cortical abnormalities are supposed to form a subgroup clinically characterized by low premorbid adjustment, early onset, incomplete remission, poor outcome, male predominance and high risk for tardive dyskinesia. A small amplitude of the event-related P3 (P300) potential could be a marker of this subgroup, because the cortical neurons and their orderly laminar arrangement are crucial for the electrogenesis of P3. In a 2-year follow-up study, auditory evoked P3 was recorded in 89 stabilized schizophrenic outpatients. Patients who developed tardive dyskinesia during the follow-up had smaller P3 than matched controls. Furthermore, a small P3 was associated with low premorbid adjustment, pronounced residual symptoms, low relapse rate, and male predominance. These findings indicate that schizophrenic patients with a reduced P3 have a higher risk of developing tardive dyskinesia and correspond clinically to a schizophrenic subgroup with a supposedly neurodevelopmental disturbance.
authors.affiliation: Department of Psychiatry, Ludwig-Maximilians-Universität München, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Hegerl
authors.forename: G
authors.initials: G
authors.lastname: Juckel
authors.forename: A
authors.initials: A
authors.lastname: Müller-Schubert
authors.forename: A
authors.initials: A
authors.lastname: Pietzcker
authors.forename: W
authors.initials: W
authors.lastname: Gaebel
mesh_terms: D000328:Adult; D017668:Age of Onset; D001712:Biperiden / Q000009:adverse effects* / Q000627:therapeutic use*; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000209:etiology*; D005071:Evoked Potentials; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010464:Perazine / Q000009:adverse effects* / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D012720:Severity of Illness Index; D012737:Sex Factors
chemical_list: D001712:Biperiden; D010464:Perazine; D003024:Clozapine